{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T05:04:49Z","timestamp":1725080689175},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00595-015-1282-4","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T16:30:01Z","timestamp":1448555401000},"page":"1068-1075","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Primary surgery as a frontline treatment for synchronous metastatic gastrointestinal stromal tumors: an analysis of the Kinki GIST registry"],"prefix":"10.1007","volume":"46","author":[{"given":"Shinsuke","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshirou","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,26]]},"reference":[{"key":"1282_CR1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1517\/14656566.2014.937707","volume":"15","author":"T Nishida","year":"2014","unstructured":"Nishida T, Doi T, Naito Y. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother. 2014;15:1979\u201389.","journal-title":"Expert Opin Pharmacother"},{"key":"1282_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/annonc\/mdp310","volume":"21","author":"C Mussi","year":"2010","unstructured":"Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, et al. Post-imatinib surgery in advanced\/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21:403\u20138.","journal-title":"Ann Oncol"},{"key":"1282_CR3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jss.2012.07.005","volume":"177","author":"V Zaydfudim","year":"2012","unstructured":"Zaydfudim V, Okuno SH, Que FG, Nagorney DM, Donohue JH. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. J Surg Res. 2012;177:248\u201354.","journal-title":"J Surg Res"},{"key":"1282_CR4","doi-asserted-by":"crossref","unstructured":"Rubi\u00f3-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015. [Epub ahead of print].","DOI":"10.1245\/s10434-014-4360-8"},{"key":"1282_CR5","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cncr.26650","volume":"118","author":"RS Turley","year":"2012","unstructured":"Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, Marsh JW, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2012;118:3571\u20138.","journal-title":"Cancer"},{"key":"1282_CR6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/ans.12199","volume":"84","author":"FC Cananzi","year":"2014","unstructured":"Cananzi FC, Belgaumkar A, Lorenzi B, Mudan S. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. ANZ J Surg. 2014;84:937\u201342.","journal-title":"ANZ J Surg."},{"key":"1282_CR7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12029-014-9663-2","volume":"45","author":"H Takaki","year":"2014","unstructured":"Takaki H, Litchman T, Covey A, Cornelis F, Maybody M, Getrajdman GI, et al. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. J Gastrointest Cancer. 2014;45:494\u20139.","journal-title":"J Gastrointest Cancer."},{"key":"1282_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jvir.2012.11.021","volume":"24","author":"T Yamanaka","year":"2013","unstructured":"Yamanaka T, Takaki H, Nakatsuka A, Uraki J, Fujimori M, Hasegawa T, et al. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol. 2013;24:341\u20136.","journal-title":"J Vasc Interv Radiol"},{"key":"1282_CR9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s00595-013-0690-6","volume":"44","author":"A Sasaki","year":"2014","unstructured":"Sasaki A, Nitta H, Otsuka K, Fujiwara H, Takahara T, Wakabayashi G. Single-port versus multiport laparoscopic resection for gastric gastrointestinal stromal tumors: a case-matched comparison. Surg Today. 2014;44:1282\u20136.","journal-title":"Surg Today"},{"key":"1282_CR10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- vs. higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620\u20135.","journal-title":"J Clin Oncol"},{"key":"1282_CR11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626\u201332.","journal-title":"J Clin Oncol"},{"key":"1282_CR12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"1282_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"1282_CR14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","volume":"40","author":"S Bauer","year":"2014","unstructured":"Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2014analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"1282_CR15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097\u2013104.","journal-title":"Lancet"},{"key":"1282_CR16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Sch\u00fctte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265\u201372.","journal-title":"JAMA"},{"key":"1282_CR17","doi-asserted-by":"crossref","unstructured":"P\u00e9rol D, Ray-Coquard I, Nguyen BB, Adenis A, Rios M, Bertucci F, et al. Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): results from the BFR14 phase III trial of the French Sarcoma Group. J Clin Oncol. 2012;30:10092 [abstract].","DOI":"10.1200\/jco.2012.30.15_suppl.10092"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-015-1282-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-015-1282-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-015-1282-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T23:25:51Z","timestamp":1599866751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-015-1282-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,26]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1007\/s00595-015-1282-4","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,26]]}}}